Risk factors for thrombotic microangiopathy in allogeneic hematopoietic stem cell recipients receiving GVHD prophylaxis with tacrolimus plus MTX or sirolimus
Transplantation-associated thrombotic microangiopathy (TA-TMA) is a feared complication of allogeneic hematopoietic SCT (HSCT) owing to its high mortality rate. The use of calcineurin inhibitors or sirolimus (SIR) for GVHD prophylaxis has been suggested as a potential risk factor. However, the impac...
Saved in:
Published in | Bone marrow transplantation (Basingstoke) Vol. 49; no. 5; pp. 684 - 690 |
---|---|
Main Authors | , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Basingstoke
Nature Publishing Group
01.05.2014
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Transplantation-associated thrombotic microangiopathy (TA-TMA) is a feared complication of allogeneic hematopoietic SCT (HSCT) owing to its high mortality rate. The use of calcineurin inhibitors or sirolimus (SIR) for GVHD prophylaxis has been suggested as a potential risk factor. However, the impact of tacrolimus (TAC) and SIR combinations on the increased risk of TA-TMA is currently not well defined. We retrospectively analyzed the incidence of TA-TMA in 102 allogeneic HSCT recipients who consecutively received TAC plus SIR (TAC/SIR) (n=68) or plus MTX (TAC/MTX)±ATG (n=34) for GVHD prophylaxis. No significant differences were observed in the incidence of TA-TMA between patients receiving TAC/SIR vs TAC/MTX±ATG (7.4% vs 8.8%, P=0.8). Only grade III-IV acute GVHD, previous HSCT and serum levels of TAC >25 ng/mL were associated with a greater risk of TA-TMA. Patients developing TA-TMA have significantly poorer survival (P<0.001); however, TA-TMA ceased to be an independent prognostic factor when it was included in a multivariate model. In conclusion, the combination of TAC/SIR does not appear to pose a higher risk of TA-TMA. By contrast, we identified three different risk groups for developing TA-TMA. |
---|---|
AbstractList | Transplantation-associated thrombotic microangiopathy (TA-TMA) is a feared complication of allogeneic hematopoietic SCT (HSCT) owing to its high mortality rate. The use of calcineurin inhibitors or sirolimus (SIR) for GVHD prophylaxis has been suggested as a potential risk factor. However, the impact of tacrolimus (TAC) and SIR combinations on the increased risk of TA-TMA is currently not well defined. We retrospectively analyzed the incidence of TA-TMA in 102 allogeneic HSCT recipients who consecutively received TAC plus SIR (TAC/SIR) (n = 68) or plus MTX (TAC/MTX) ± ATG (n = 34) for GVHD prophylaxis. No significant differences were observed in the incidence of TA-TMA between patients receiving TAC/SIR vs TAC/MTX [+ or -] ATG (7.4% vs 8.8%, P = 0.8). Only grade III-IV acute GVHD, previous HSCT and serum levels of TAC >25 ng/mL were associated with a greater risk of TA-TMA. Patients developing TA-TMA have significantly poorer survival (P < 0.001);however, TA-TMA ceased to be an independent prognostic factor when it was included in a multivariate model. In conclusion, the combination of TAC/SIR does not appear to pose a higher risk of TA-TMA. By contrast, we identified three different risk groups for developing TA-TMA. Bone Marrow Transplantation (2014) 49, 684-690; doi: 10.1038/bmt.2014.17; published online 24 February 2014 Keywords: transplant-associated thrombotic microangiopathy; allo-SCT; tacrolimus; sirolimus; risk factors Transplantation-associated thrombotic microangiopathy (TA-TMA) is a feared complication of allogeneic hematopoietic SCT (HSCT) owing to its high mortality rate. The use of calcineurin inhibitors or sirolimus (SIR) for GVHD prophylaxis has been suggested as a potential risk factor. However, the impact of tacrolimus (TAC) and SIR combinations on the increased risk of TA-TMA is currently not well defined. We retrospectively analyzed the incidence of TA-TMA in 102 allogeneic HSCT recipients who consecutively received TAC plus SIR (TAC/SIR) (n=68) or plus MTX (TAC/MTX)±ATG (n=34) for GVHD prophylaxis. No significant differences were observed in the incidence of TA-TMA between patients receiving TAC/SIR vs TAC/MTX±ATG (7.4% vs 8.8%, P=0.8). Only grade III–IV acute GVHD, previous HSCT and serum levels of TAC >25 ng/mL were associated with a greater risk of TA-TMA. Patients developing TA-TMA have significantly poorer survival (P<0.001); however, TA-TMA ceased to be an independent prognostic factor when it was included in a multivariate model. In conclusion, the combination of TAC/SIR does not appear to pose a higher risk of TA-TMA. By contrast, we identified three different risk groups for developing TA-TMA. Transplantation-associated thrombotic microangiopathy (TA-TMA) is a feared complication of allogeneic hematopoietic SCT (HSCT) owing to its high mortality rate. The use of calcineurin inhibitors or sirolimus (SIR) for GVHD prophylaxis has been suggested as a potential risk factor. However, the impact of tacrolimus (TAC) and SIR combinations on the increased risk of TA-TMA is currently not well defined. We retrospectively analyzed the incidence of TA-TMA in 102 allogeneic HSCT recipients who consecutively received TAC plus SIR (TAC/SIR) (n=68) or plus MTX (TAC/MTX) plus or minus ATG (n=34) for GVHD prophylaxis. No significant differences were observed in the incidence of TA-TMA between patients receiving TAC/SIR vs TAC/MTX plus or minus ATG (7.4% vs 8.8%, P=0.8). Only grade III-IV acute GVHD, previous HSCT and serum levels of TAC >25 ng/mL were associated with a greater risk of TA-TMA. Patients developing TA-TMA have significantly poorer survival (P<0.001); however, TA-TMA ceased to be an independent prognostic factor when it was included in a multivariate model. In conclusion, the combination of TAC/SIR does not appear to pose a higher risk of TA-TMA. By contrast, we identified three different risk groups for developing TA-TMA. Transplantation-associated thrombotic microangiopathy (TA-TMA) is a feared complication of allogeneic hematopoietic SCT (HSCT) owing to its high mortality rate. The use of calcineurin inhibitors or sirolimus (SIR) for GVHD prophylaxis has been suggested as a potential risk factor. However, the impact of tacrolimus (TAC) and SIR combinations on the increased risk of TA-TMA is currently not well defined. We retrospectively analyzed the incidence of TA-TMA in 102 allogeneic HSCT recipients who consecutively received TAC plus SIR (TAC/SIR) (n = 68) or plus MTX (TAC/MTX) ± ATG (n = 34) for GVHD prophylaxis. No significant differences were observed in the incidence of TA-TMA between patients receiving TAC/SIR vs TAC/MTX [+ or -] ATG (7.4% vs 8.8%, P = 0.8). Only grade III-IV acute GVHD, previous HSCT and serum levels of TAC >25 ng/mL were associated with a greater risk of TA-TMA. Patients developing TA-TMA have significantly poorer survival (P < 0.001);however, TA-TMA ceased to be an independent prognostic factor when it was included in a multivariate model. In conclusion, the combination of TAC/SIR does not appear to pose a higher risk of TA-TMA. By contrast, we identified three different risk groups for developing TA-TMA. Transplantation-associated thrombotic microangiopathy (TA-TMA) is a feared complication of allogeneic hematopoietic SCT (HSCT) owing to its high mortality rate. The use of calcineurin inhibitors or sirolimus (SIR) for GVHD prophylaxis has been suggested as a potential risk factor. However, the impact of tacrolimus (TAC) and SIR combinations on the increased risk of TA-TMA is currently not well defined. We retrospectively analyzed the incidence of TA-TMA in 102 allogeneic HSCT recipients who consecutively received TAC plus SIR (TAC/SIR) (n=68) or plus MTX (TAC/MTX)±ATG (n=34) for GVHD prophylaxis. No significant differences were observed in the incidence of TA-TMA between patients receiving TAC/SIR vs TAC/MTX±ATG (7.4% vs 8.8%, P=0.8). Only grade III-IV acute GVHD, previous HSCT and serum levels of TAC >25ng/mL were associated with a greater risk of TA-TMA. Patients developing TA-TMA have significantly poorer survival (P<0.001); however, TA-TMA ceased to be an independent prognostic factor when it was included in a multivariate model. In conclusion, the combination of TAC/SIR does not appear to pose a higher risk of TA-TMA. By contrast, we identified three different risk groups for developing TA-TMA. |
Audience | Academic |
Author | VAZQUEZ, L GUERRERO, C SANCHEZ-GUIJO, F LABRADOR, J PEREZ-LOPEZ, E GONZALEZ-PORRAS, J. R CABALLERO, D DIEZ-CAMPELO, M PEREZ-LOPEZ, R LOPEZ-CORRAL, L LOPEZ-GODINO, O CABRERO-CALVO, M DEL CANIZO, M. C PEREZ-SIMON, J. A ALBERCA, I |
Author_xml | – sequence: 1 givenname: J surname: LABRADOR fullname: LABRADOR, J organization: Department of Hematology, Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain – sequence: 2 givenname: L surname: LOPEZ-CORRAL fullname: LOPEZ-CORRAL, L organization: Department of Hematology, Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain – sequence: 3 givenname: I surname: ALBERCA fullname: ALBERCA, I organization: Department of Hematology, Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain – sequence: 4 givenname: M. C surname: DEL CANIZO fullname: DEL CANIZO, M. C organization: Department of Hematology, Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain – sequence: 5 givenname: J. A surname: PEREZ-SIMON fullname: PEREZ-SIMON, J. A organization: Department of Hematology, Hospital Universitario/Instituto de Biomedicina (IBIS)/CSIC, Seville, Spain – sequence: 6 givenname: J. R surname: GONZALEZ-PORRAS fullname: GONZALEZ-PORRAS, J. R organization: Department of Hematology, Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain – sequence: 7 givenname: D surname: CABALLERO fullname: CABALLERO, D organization: Department of Hematology, Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain – sequence: 8 givenname: O surname: LOPEZ-GODINO fullname: LOPEZ-GODINO, O organization: Department of Hematology, Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain – sequence: 9 givenname: L surname: VAZQUEZ fullname: VAZQUEZ, L organization: Department of Hematology, Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain – sequence: 10 givenname: M surname: CABRERO-CALVO fullname: CABRERO-CALVO, M organization: Department of Hematology, Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain – sequence: 11 givenname: R surname: PEREZ-LOPEZ fullname: PEREZ-LOPEZ, R organization: Pharmacy Department, Hospital Universitario de Salamanca, Salamanca, Spain – sequence: 12 givenname: M surname: DIEZ-CAMPELO fullname: DIEZ-CAMPELO, M organization: Department of Hematology, Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain – sequence: 13 givenname: F surname: SANCHEZ-GUIJO fullname: SANCHEZ-GUIJO, F organization: Department of Hematology, Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain – sequence: 14 givenname: E surname: PEREZ-LOPEZ fullname: PEREZ-LOPEZ, E organization: Department of Hematology, Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain – sequence: 15 givenname: C surname: GUERRERO fullname: GUERRERO, C organization: Centro de Investigación del Cancer, IBMC/CSIC-USAL, Salamanca, Spain |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=28475583$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/24566710$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kt9rFDEQx4NU7LX65LsERBFkz82v3c1jqdoKFUGq-BayueQ2NZusSVa9P8b_1Sw9rRWRQBJmPpOZyXyPwIEPXgPwENVrVJPuRT_mNa4RXaP2Dlgh2jYVIw07AKsaN11FSMMPwVFKV3WBaM3ugUNMWdO0qF6BH-9t-gyNVDnEBE2IMA8xjH3IVsHRqhik39owyTzsoPVQOhe22uviHfQoc5iC1Qubsh6h0s7BqJWdrPY5LVdtv1q_hWcfz1_CKYZp2Dn53Sb4zeYBZlkSODvOCU6ubG8vP8FSQrJ7631w10iX9IP9eQw-vH51eXpeXbw7e3N6clEpRkmumEEGcclabiTRG4RNRxjRtVGm73jplTNZvD1RmDHEOSdNT_HGYGp006uGHINn1--WCr_MOmUx2rQ0I70OcxKIMcopJR0p6OO_0KswR1-qE7ihGLVdh-n_KMQwojUnCN9QW-m0sN6EHKVaUosT0nQdbTlbqPU_qLI2ugyoaMHYYr8V8PSPgEFLl4cU3Jxt8Ok2-PwaLFNIKWojpmhHGXcC1WLRlijaEou2BGoL_Wjf09yPevOb_SWmAjzZAzIp6UyUXtl0w5WsjJUv_AmrQtis |
CODEN | BMTRE9 |
CitedBy_id | crossref_primary_10_1111_bjh_13344 crossref_primary_10_1111_ijlh_13130 crossref_primary_10_1111_bjh_19506 crossref_primary_10_1053_j_ackd_2021_11_003 crossref_primary_10_3925_jjtc_69_411 crossref_primary_10_1007_s10157_021_02131_7 crossref_primary_10_1016_j_jtct_2022_11_015 crossref_primary_10_2491_jjsth_25_725 crossref_primary_10_1111_bjh_16457 crossref_primary_10_1016_j_arcped_2018_09_011 crossref_primary_10_1097_MOH_0000000000000687 crossref_primary_10_1111_ejh_12996 crossref_primary_10_1177_1060028015593369 crossref_primary_10_1038_s41409_018_0293_3 crossref_primary_10_3389_fonc_2021_683263 crossref_primary_10_1016_j_bbmt_2020_09_018 crossref_primary_10_1016_j_jtct_2022_01_003 crossref_primary_10_1016_j_blre_2014_11_001 crossref_primary_10_1016_j_tmrv_2016_06_002 crossref_primary_10_1038_bmt_2014_228 crossref_primary_10_1038_bmt_2015_161 crossref_primary_10_1177_107327481502200109 crossref_primary_10_1182_bloodadvances_2019001315 crossref_primary_10_1016_j_tranon_2021_101081 crossref_primary_10_1016_j_bbmt_2018_10_015 crossref_primary_10_1016_j_semnephrol_2023_151345 crossref_primary_10_1182_blood_2014_03_564997 crossref_primary_10_1097_MD_0000000000001200 crossref_primary_10_1002_ajh_25922 crossref_primary_10_1016_j_thromres_2016_04_017 crossref_primary_10_1111_petr_14366 crossref_primary_10_1177_1078155216628324 crossref_primary_10_1182_bloodadvances_2019001242 crossref_primary_10_1038_bmt_2016_87 crossref_primary_10_1080_17474086_2023_2162501 crossref_primary_10_1056_NEJMra1404711 crossref_primary_10_1182_bloodadvances_2021004530 crossref_primary_10_1182_blood_2016_11_743104 crossref_primary_10_1053_j_ajkd_2018_06_013 crossref_primary_10_1093_qjmed_hcaa072 crossref_primary_10_1016_j_bbmt_2015_10_002 |
Cites_doi | 10.1038/sj.bmt.1705976 10.1016/j.bbmt.2010.09.017 10.1002/ajh.20648 10.1634/theoncologist.2009-0067 10.1097/TP.0b013e3181ba0a13 10.1097/TP.0b013e3181f24e8d 10.1038/sj.bmt.1705758 10.1111/j.1537-2995.2004.00700.x 10.1038/bmt.2012.175 10.1016/j.bbmt.2005.07.012 10.1182/blood-2011-02-321315 10.1038/bmt.2011.65 10.1002/cncr.24531 10.3324/haematol.2012.065599 10.1038/bmt.2009.230 10.3324/haematol.10699 10.1038/bmt.2011.46 10.3324/haematol.2012.067140 10.1111/j.1600-0609.2011.01685.x 10.1016/j.bbmt.2004.03.002 10.1002/pbc.22861 10.1182/blood-2009-03-207563 10.1097/01.tp.0000297998.33418.7e 10.1016/j.bbmt.2012.10.006 10.1016/j.bbmt.2006.11.020 10.1097/01.TP.0000092522.36410.D0 10.1097/CCO.0b013e3280148a2f 10.1046/j.1537-2995.2003.00282.x 10.2215/CJN.02070508 10.1016/S0140-6736(02)08907-9 10.1016/j.bbmt.2005.06.001 10.1182/asheducation.V2012.1.617.3798924 10.1182/blood-2010-01-265728 10.1016/j.transci.2007.03.004 10.1016/j.bbmt.2005.04.007 |
ContentType | Journal Article |
Copyright | 2015 INIST-CNRS COPYRIGHT 2014 Nature Publishing Group Copyright Nature Publishing Group May 2014 Macmillan Publishers Limited 2014. |
Copyright_xml | – notice: 2015 INIST-CNRS – notice: COPYRIGHT 2014 Nature Publishing Group – notice: Copyright Nature Publishing Group May 2014 – notice: Macmillan Publishers Limited 2014. |
DBID | IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 3V. 7QO 7QP 7T5 7U9 7X7 7XB 88E 8AO 8FD 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FR3 FYUFA GHDGH GNUQQ H94 HCIFZ K9. LK8 M0S M1P M7N M7P P64 PQEST PQQKQ PQUKI |
DOI | 10.1038/bmt.2014.17 |
DatabaseName | Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Central (Corporate) Biotechnology Research Abstracts Calcium & Calcified Tissue Abstracts Immunology Abstracts Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Technology Research Database ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences Health & Medical Collection (Alumni Edition) Medical Database Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Biotechnology and BioEngineering Abstracts ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef ProQuest Central Student Technology Research Database ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central Health Research Premium Collection Biotechnology Research Abstracts Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Collection AIDS and Cancer Research Abstracts ProQuest Medical Library (Alumni) Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Immunology Abstracts Engineering Research Database ProQuest One Academic Calcium & Calcified Tissue Abstracts ProQuest Central (Alumni) |
DatabaseTitleList | ProQuest Central Student AIDS and Cancer Research Abstracts MEDLINE ProQuest Central Student |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1476-5365 |
EndPage | 690 |
ExternalDocumentID | 3295524111 A368847952 10_1038_bmt_2014_17 24566710 28475583 |
Genre | Journal Article |
GroupedDBID | --- -Q- .55 .XZ 0R~ 23N 2WC 36B 39C 3V. 4.4 53G 5GY 5RE 6J9 70F 7X7 88E 8AO 8FI 8FJ 8R4 8R5 AADWK AANZL AAPBV AAWBL AAYJO AAZLF ABAWZ ABDBF ABDEU ABFLS ABLJU ABPTK ABUWG ACBMV ACBRV ACBYP ACDSR ACGFO ACGFS ACIGE ACIWK ACKTT ACPRK ACRQY ACTTH ACVWB ADBBV ADFRT ADGIM ADHDB ADMDM ADQMX ADYYL AEDAW AEFTE AEJRE AENEX AEXYK AFFNX AFKRA AFRAH AFSHS AGAYW AGEZK AGGBP AGHAI AHMBA AHSBF AILAN AJDOV AJRNO ALFFA ALMA_UNASSIGNED_HOLDINGS AMRJV AMYLF ASPBG AVWKF AXYYD AZFZN B0M BAWUL BBAFP BBNVY BENPR BHPHI BKKNO BPHCQ BVXVI CS3 DIK DNIVK DU5 E3Z EAD EAP EBC EBD EBLON EBS EE. EIOEI EJD EMB EMK EMOBN EPL ESX EX3 F5P FDQFY FEDTE FERAY FIZPM FRP FSGXE FYUFA GX1 HCIFZ HVGLF HZ~ IAO IH2 IHR IHW INH INR IQODW ITC J5H JSO JZLTJ KQ8 M1P M7P N95 N9A NAO NQJWS NYICJ O9- OK1 OVD P2P PQEST PQQKQ PQUKI PROAC PSQYO Q2X RNT RNTTT SNX SNYQT SRMVM SV3 SWTZT TAOOD TBHMF TDRGL TEORI TR2 TSG TUS UDS UKHRP W2D X7M ZA5 ZGI ZXP 406 AASML AATNV ABAKF ABJNI ABZZP ACAOD ACMJI ACZOJ AEFQL AEMSY AEVLU AFBBN AFNRJ AGQEE AIGIU AJCLW CCPQU CGR CUY CVF DPUIP ECM EIF FIGPU HMCUK IWAJR LGEZI LOTEE NADUK NPM NXXTH SOHCF ~8M AAYXX ALIPV CITATION AAYFA ABGIJ 7QO 7QP 7T5 7U9 7XB 8FD 8FE 8FH 8FK AZQEC DWQXO FR3 GNUQQ H94 K9. LK8 M7N P64 |
ID | FETCH-LOGICAL-c543t-5f1f19a579fa3ed12f8353e0fcfb8945695aa57b3c255199936b42df24fe6bc63 |
IEDL.DBID | BENPR |
ISSN | 0268-3369 |
IngestDate | Fri Aug 16 04:32:08 EDT 2024 Fri Sep 13 09:29:48 EDT 2024 Fri Sep 13 09:41:55 EDT 2024 Thu Feb 22 23:41:36 EST 2024 Fri Feb 02 04:27:52 EST 2024 Tue Aug 20 22:09:33 EDT 2024 Fri Aug 23 01:32:10 EDT 2024 Thu May 23 23:19:46 EDT 2024 Fri Nov 25 16:33:34 EST 2022 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 5 |
Keywords | Antineoplastic agent Calcineurin inhibitor Sirolimus Stem cell Hematopoietic cell Homograft Cardiovascular disease Epidemiology Thrombohemolytic microangiopathy Macrocycle Vascular disease Prevention Allogeneic hematopoietic stem cell transplantation allo-SCT Graft Protein synthesis inhibitor Immunopathology Graft versus host disease risk factors Hematology Lactone Recipient Macrolide transplant-associated thrombotic microangiopathy Immunomodulator Antibiotic Tacrolimus Risk factor Immunosuppressive agent |
Language | English |
License | CC BY 4.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c543t-5f1f19a579fa3ed12f8353e0fcfb8945695aa57b3c255199936b42df24fe6bc63 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://digital.csic.es/bitstream/10261/134585/5/Risk%20factors%20thrombotic.pdf |
PMID | 24566710 |
PQID | 1521409312 |
PQPubID | 36075 |
PageCount | 7 |
ParticipantIDs | proquest_miscellaneous_1554944383 proquest_journals_2642178824 proquest_journals_1521409312 gale_infotracmisc_A368847952 gale_infotracacademiconefile_A368847952 gale_healthsolutions_A368847952 crossref_primary_10_1038_bmt_2014_17 pubmed_primary_24566710 pascalfrancis_primary_28475583 |
PublicationCentury | 2000 |
PublicationDate | 2014-05-01 |
PublicationDateYYYYMMDD | 2014-05-01 |
PublicationDate_xml | – month: 05 year: 2014 text: 2014-05-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | Basingstoke |
PublicationPlace_xml | – name: Basingstoke – name: England – name: London |
PublicationTitle | Bone marrow transplantation (Basingstoke) |
PublicationTitleAlternate | Bone Marrow Transplant |
PublicationYear | 2014 |
Publisher | Nature Publishing Group |
Publisher_xml | – name: Nature Publishing Group |
References | 19965688 - Blood. 2010 Feb 4;115(5):1098-105 14724447 - Transplantation. 2004 Jan 15;77(1):129-31 14962323 - Transfusion. 2004 Feb;44(2):294-304 23065527 - Haematologica. 2013 Apr;98 (4):526-32 17229640 - Haematologica. 2007 Jan;92(1):95-100 15983555 - Biol Blood Marrow Transplant. 2005 Jul;11(7):551-7 21557459 - Pediatr Blood Cancer. 2011 Jul 15;57(1):142-6 19684072 - Oncologist. 2009 Aug;14 (8):769-79 20508174 - Blood. 2010 May 27;115(21):4316-7; author reply 4317 19144762 - Clin J Am Soc Nephrol. 2009 Feb;4(2):345-53 17382253 - Biol Blood Marrow Transplant. 2007 Apr;13(4):469-77 23000644 - Bone Marrow Transplant. 2013 Feb;48(2):278-83 17272988 - Curr Opin Oncol. 2007 Mar;19(2):148-54 18209725 - Bone Marrow Transplant. 2008 May;41(9):813-20 12086762 - Lancet. 2002 Jun 15;359(9323):2078-83 19642176 - Cancer. 2009 Oct 15;115(20):4715-26 19898203 - Transplantation. 2009 Nov 15;88(9):1081-7 22974354 - Eur J Haematol. 2011 Dec;87(6):503-9 21460864 - Bone Marrow Transplant. 2011 Dec;46(12):1495-502 19718063 - Bone Marrow Transplant. 2010 Apr;45(4):689-93 16041306 - Biol Blood Marrow Transplant. 2005 Aug;11(8):571-5 16755559 - Am J Hematol. 2006 Jul;81(7):525-31 16275594 - Biol Blood Marrow Transplant. 2005 Nov;11(11):912-20 21596850 - Blood. 2011 Aug 11;118(6):1452-62 20717073 - Transplantation. 2010 Oct 27;90(8):918-26 7581076 - Bone Marrow Transplant. 1995 Jun;15(6):825-8 23078784 - Biol Blood Marrow Transplant. 2013 Feb;19(2):298-304 23233643 - Hematology Am Soc Hematol Educ Program. 2012;2012:617-25 18192907 - Transplantation. 2008 Jan 15;85(1):22-8 22689677 - Haematologica. 2012 Dec;97(12):1882-9 12519434 - Transfusion. 2003 Jan;43(1):78-84 17569587 - Transfus Apher Sci. 2007 Jun;36(3):297-304 21383682 - Bone Marrow Transplant. 2011 Nov;46(11):1399-408 20932925 - Biol Blood Marrow Transplant. 2011 Jun;17(6):916-22 15205669 - Biol Blood Marrow Transplant. 2004 Jul;10(7):484-93 17603513 - Bone Marrow Transplant. 2007 Oct;40(8):709-19 D Przepiorka (BFbmt201417_CR26) 1995; 15 CM Nester (BFbmt201417_CR6) 2012; 2012 N Worel (BFbmt201417_CR10) 2007; 36 E Willems (BFbmt201417_CR11) 2010; 45 AS Paramesh (BFbmt201417_CR19) 2004; 77 JA Perez-Simon (BFbmt201417_CR25) 2012; 98 BC Biedermann (BFbmt201417_CR27) 2002; 359 T Ruutu (BFbmt201417_CR30) 2007; 92 A Gratwohl (BFbmt201417_CR36) 2009; 115 JN George (BFbmt201417_CR2) 2004; 44 K Siami (BFbmt201417_CR13) 2008; 85 E Carreras (BFbmt201417_CR5) 2011; 46 BS Cho (BFbmt201417_CR1) 2010; 90 BL Laskin (BFbmt201417_CR4) 2011; 118 VT Ho (BFbmt201417_CR29) 2005; 11 J Pidala (BFbmt201417_CR24) 2012; 97 D Ghez (BFbmt201417_CR16) 2009; 88 SK Khaled (BFbmt201417_CR22) 2013; 48 GA Hale (BFbmt201417_CR9) 2005; 11 LL Rosenbeck (BFbmt201417_CR23) 2011; 17 L Oberic (BFbmt201417_CR33) 2009; 14 ED Batts (BFbmt201417_CR3) 2007; 40 O Ringden (BFbmt201417_CR28) 2011; 87 R Rodriguez (BFbmt201417_CR17) 2010; 115 J Rosenthal (BFbmt201417_CR21) 2011; 57 B Oran (BFbmt201417_CR35) 2007; 13 H Nakamae (BFbmt201417_CR8) 2006; 81 BS Cho (BFbmt201417_CR31) 2008; 41 K Kojouri (BFbmt201417_CR7) 2007; 19 JA Lopes (BFbmt201417_CR32) 2011; 46 S Changsirikulchai (BFbmt201417_CR12) 2009; 4 MA Kharfan-Dabaja (BFbmt201417_CR34) 2010; 115 C Cutler (BFbmt201417_CR18) 2005; 11 A Shimoni (BFbmt201417_CR14) 2004; 10 C Sarkodee-Adoo (BFbmt201417_CR15) 2003; 43 S Shayani (BFbmt201417_CR20) 2012; 19 |
References_xml | – volume: 15 start-page: 825 year: 1995 ident: BFbmt201417_CR26 publication-title: Bone Marrow Transplant contributor: fullname: D Przepiorka – volume: 41 start-page: 813 year: 2008 ident: BFbmt201417_CR31 publication-title: Bone Marrow Transplant doi: 10.1038/sj.bmt.1705976 contributor: fullname: BS Cho – volume: 17 start-page: 916 year: 2011 ident: BFbmt201417_CR23 publication-title: Biol Blood Marrow Transplant doi: 10.1016/j.bbmt.2010.09.017 contributor: fullname: LL Rosenbeck – volume: 81 start-page: 525 year: 2006 ident: BFbmt201417_CR8 publication-title: Am J Hematol doi: 10.1002/ajh.20648 contributor: fullname: H Nakamae – volume: 14 start-page: 769 year: 2009 ident: BFbmt201417_CR33 publication-title: Oncologist doi: 10.1634/theoncologist.2009-0067 contributor: fullname: L Oberic – volume: 88 start-page: 1081 year: 2009 ident: BFbmt201417_CR16 publication-title: Transplantation doi: 10.1097/TP.0b013e3181ba0a13 contributor: fullname: D Ghez – volume: 90 start-page: 918 year: 2010 ident: BFbmt201417_CR1 publication-title: Transplantation doi: 10.1097/TP.0b013e3181f24e8d contributor: fullname: BS Cho – volume: 40 start-page: 709 year: 2007 ident: BFbmt201417_CR3 publication-title: Bone Marrow Transplant doi: 10.1038/sj.bmt.1705758 contributor: fullname: ED Batts – volume: 44 start-page: 294 year: 2004 ident: BFbmt201417_CR2 publication-title: Transfusion doi: 10.1111/j.1537-2995.2004.00700.x contributor: fullname: JN George – volume: 48 start-page: 278 year: 2013 ident: BFbmt201417_CR22 publication-title: Bone Marrow Transplant doi: 10.1038/bmt.2012.175 contributor: fullname: SK Khaled – volume: 11 start-page: 912 year: 2005 ident: BFbmt201417_CR9 publication-title: Biol Blood Marrow Transplant doi: 10.1016/j.bbmt.2005.07.012 contributor: fullname: GA Hale – volume: 118 start-page: 1452 year: 2011 ident: BFbmt201417_CR4 publication-title: Blood doi: 10.1182/blood-2011-02-321315 contributor: fullname: BL Laskin – volume: 46 start-page: 1495 year: 2011 ident: BFbmt201417_CR5 publication-title: Bone Marrow Transplant doi: 10.1038/bmt.2011.65 contributor: fullname: E Carreras – volume: 115 start-page: 4715 year: 2009 ident: BFbmt201417_CR36 publication-title: Cancer doi: 10.1002/cncr.24531 contributor: fullname: A Gratwohl – volume: 98 start-page: 526 year: 2012 ident: BFbmt201417_CR25 publication-title: Haematologica doi: 10.3324/haematol.2012.065599 contributor: fullname: JA Perez-Simon – volume: 45 start-page: 689 year: 2010 ident: BFbmt201417_CR11 publication-title: Bone Marrow Transplant doi: 10.1038/bmt.2009.230 contributor: fullname: E Willems – volume: 92 start-page: 95 year: 2007 ident: BFbmt201417_CR30 publication-title: Haematologica doi: 10.3324/haematol.10699 contributor: fullname: T Ruutu – volume: 46 start-page: 1399 year: 2011 ident: BFbmt201417_CR32 publication-title: Bone Marrow Transplant doi: 10.1038/bmt.2011.46 contributor: fullname: JA Lopes – volume: 97 start-page: 1882 year: 2012 ident: BFbmt201417_CR24 publication-title: Haematologica doi: 10.3324/haematol.2012.067140 contributor: fullname: J Pidala – volume: 87 start-page: 503 year: 2011 ident: BFbmt201417_CR28 publication-title: Eur J Haematol doi: 10.1111/j.1600-0609.2011.01685.x contributor: fullname: O Ringden – volume: 10 start-page: 484 year: 2004 ident: BFbmt201417_CR14 publication-title: Biol Blood Marrow Transplant doi: 10.1016/j.bbmt.2004.03.002 contributor: fullname: A Shimoni – volume: 57 start-page: 142 year: 2011 ident: BFbmt201417_CR21 publication-title: Pediatr Blood Cancer doi: 10.1002/pbc.22861 contributor: fullname: J Rosenthal – volume: 115 start-page: 1098 year: 2010 ident: BFbmt201417_CR17 publication-title: Blood doi: 10.1182/blood-2009-03-207563 contributor: fullname: R Rodriguez – volume: 85 start-page: 22 year: 2008 ident: BFbmt201417_CR13 publication-title: Transplantation doi: 10.1097/01.tp.0000297998.33418.7e contributor: fullname: K Siami – volume: 19 start-page: 298 year: 2012 ident: BFbmt201417_CR20 publication-title: Biol Blood Marrow Transplant doi: 10.1016/j.bbmt.2012.10.006 contributor: fullname: S Shayani – volume: 13 start-page: 469 year: 2007 ident: BFbmt201417_CR35 publication-title: Biol Blood Marrow Transplant doi: 10.1016/j.bbmt.2006.11.020 contributor: fullname: B Oran – volume: 77 start-page: 129 year: 2004 ident: BFbmt201417_CR19 publication-title: Transplantation doi: 10.1097/01.TP.0000092522.36410.D0 contributor: fullname: AS Paramesh – volume: 19 start-page: 148 year: 2007 ident: BFbmt201417_CR7 publication-title: Curr Opin Oncol doi: 10.1097/CCO.0b013e3280148a2f contributor: fullname: K Kojouri – volume: 43 start-page: 78 year: 2003 ident: BFbmt201417_CR15 publication-title: Transfusion doi: 10.1046/j.1537-2995.2003.00282.x contributor: fullname: C Sarkodee-Adoo – volume: 4 start-page: 345 year: 2009 ident: BFbmt201417_CR12 publication-title: Clin J Am Soc Nephrol doi: 10.2215/CJN.02070508 contributor: fullname: S Changsirikulchai – volume: 359 start-page: 2078 year: 2002 ident: BFbmt201417_CR27 publication-title: Lancet doi: 10.1016/S0140-6736(02)08907-9 contributor: fullname: BC Biedermann – volume: 11 start-page: 571 year: 2005 ident: BFbmt201417_CR29 publication-title: Biol Blood Marrow Transplant doi: 10.1016/j.bbmt.2005.06.001 contributor: fullname: VT Ho – volume: 2012 start-page: 617 year: 2012 ident: BFbmt201417_CR6 publication-title: Hematology Am Soc Hematol Educ Program doi: 10.1182/asheducation.V2012.1.617.3798924 contributor: fullname: CM Nester – volume: 115 start-page: 4316 year: 2010 ident: BFbmt201417_CR34 publication-title: Blood doi: 10.1182/blood-2010-01-265728 contributor: fullname: MA Kharfan-Dabaja – volume: 36 start-page: 297 year: 2007 ident: BFbmt201417_CR10 publication-title: Transfus Apher Sci doi: 10.1016/j.transci.2007.03.004 contributor: fullname: N Worel – volume: 11 start-page: 551 year: 2005 ident: BFbmt201417_CR18 publication-title: Biol Blood Marrow Transplant doi: 10.1016/j.bbmt.2005.04.007 contributor: fullname: C Cutler |
SSID | ssj0014405 |
Score | 2.3382103 |
Snippet | Transplantation-associated thrombotic microangiopathy (TA-TMA) is a feared complication of allogeneic hematopoietic SCT (HSCT) owing to its high mortality... |
SourceID | proquest gale crossref pubmed pascalfrancis |
SourceType | Aggregation Database Index Database |
StartPage | 684 |
SubjectTerms | Adult Aged Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy Biological and medical sciences Blood circulation disorders Bone marrow Bone marrow, stem cells transplantation. Graft versus host reaction Calcineurin Calcineurin inhibitors Care and treatment Disease prevention Dosage and administration Drug Therapy, Combination Female Graft versus host reaction Graft vs Host Disease - drug therapy Graft vs Host Disease - epidemiology Graft vs Host Disease - prevention & control Hematopoietic Stem Cell Transplantation - adverse effects Hematopoietic Stem Cell Transplantation - statistics & numerical data Hematopoietic stem cells Humans Immunosuppressive Agents - administration & dosage Immunosuppressive Agents - blood Incidence Male Medical sciences Methotrexate - administration & dosage Methotrexate - blood Middle Aged Multivariate Analysis Physiological aspects Prognosis Prophylaxis Rapamycin Retrospective Studies Risk analysis Risk Factors Risk groups Serum levels Sirolimus - administration & dosage Sirolimus - blood Stem cell transplantation Stem cells Tacrolimus Tacrolimus - administration & dosage Tacrolimus - blood Thrombotic Microangiopathies - epidemiology Thrombotic Microangiopathies - etiology Thrombotic microangiopathy Transfusions. Complications. Transfusion reactions. Cell and gene therapy Transplantation Transplantation, Homologous Young Adult |
Title | Risk factors for thrombotic microangiopathy in allogeneic hematopoietic stem cell recipients receiving GVHD prophylaxis with tacrolimus plus MTX or sirolimus |
URI | https://www.ncbi.nlm.nih.gov/pubmed/24566710 https://www.proquest.com/docview/1521409312/abstract/ https://www.proquest.com/docview/2642178824/abstract/ https://search.proquest.com/docview/1554944383 |
Volume | 49 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfR1ri9QwMNwDRBA5X2f1bo1w4Ke62yRN209yT1flDjnuZL-VJE2keNtW2wX9Mf5XZ9rsLgvql6XbSduQmWTeM4QcKSmkMRkLLTCjUDCjQz1RWMZVSZsloAEUfYDslZzeio-zeLZFpstcGAyrXJ6J_UFd1AZt5GOGGZmgrzExVhqtAKYbv2u-h9g_Cv2svpnGNtllkUCH7e7J-dXn65VHQYghnJHJNORcZj5Xb8LTsZ5jUGUk3vZdy9bcyZ_RDxrVwnq5odHFvyXRniNd7JGHXpSkxwPuH5EtWz0m9y69s_wJ-X1dtt-ob6hDQTil2BNhrmsYT-cYiKeqr2WNPYl_0bKi6IIHcrIA7Su51k1dYoojxVrPFC38FEthNJhB2eKlLdEaQd9_mZ5RmC0g7E79LFuKtl3aKYMNgeaLljZ38HN5M6Mwhbb0d5-S24vzm9Np6LsxhCYWvAtjF7koU3GSOcVtETEHwhu3E2ecTjOQw7JYAVRzA1oKFjfgUgtWOCacldpI_ozsVHVlnxMKUlVqlBWw-5XICqacnghhndSMpTp1ATlaYiFvhqIbee8s52kOyMoRWXmUBOQVYigfMkZXWzU_5jIFppvFLCBv-hG4WZFklM85gGlg2auNkQcbI2GTmQ3waIMKVtNC7h7HKYfnl2SR-1OgzVE2Av2ZR-yv4DVJB-T1CoxfxsC3ytYLfAUo8ALryQZkf6C29bdh0SVIiC_-__KX5D4u2BCleUB2uh8LewiSVKdHZDuZJSO_VeDf2YdPfwCMryGs |
link.rule.ids | 315,786,790,12083,21416,27957,27958,31754,31755,33779,33780,43345,43840,74102,74659 |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfR1db9Mw0IIhARKa-CZsbEaaxFNYYztu8jRNwCiw7gF1qG-W7dgoYk3CkkrwY_ivu0vcVpWAl6rquYnlu_N93xFypKWQ1uYsdiCMYsGsic1IYxtXLV0-Bgug6BNkL-TkUnyep_PgcGtDWuXqTuwv6qK26CM_ZliRCfYaEyfNzxinRmF0NYzQuE3uCM4FpvSN52uDC-OW6eBjyWLOZR7q80Y8OzYLTKRMxNt-UtlGIoV7-UGjWzgjPwy3-Lf22Uuhs4dkN6iP9HTA9yNyy1WPyd1pCJA_IX--lu0PGoboUFBIKc5BWJga1tMFJt_p6ntZ4xzi37SsKIbdgYQcQPvurXVTl1jWSLG_M0WvPsX2Fw1WTbb41ZXogaAfv03eU9gtIOlK_ypbiv5c2mmLQ4AWy5Y2V_Axnc0pbKEtw69PyeXZh9m7SRwmMMQ2FbyLU5_4JNfpOPeauyJhHhQ27kbeepPloHvlqQao4RYsE2xowKURrPBMeCeNlfwZ2anqyr0gFDSpzGongOO1yAumvRkJ4bw0jGUm8xE5WmFBNUOjDdUHyHmmAFkKkaWScUQOEUNqqBJds6c65TIDQZunLCJv-hXIoN21tjrUGcA2sNXV1sr9rZXAWHYLfLBFBettoURP04zD_1dkoQLntwr1IbCZecL-Ct6QcURer8H4Zkx2q1y9xEeA0S6wh2xEng_Utnk3HLoErfDl_x9-SO5NZtNzdf7p4sseuY-HN2Rp7pOd7nrpXoEm1ZmDnl1uAF52HZk |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfR1db9Mw0IIhTUho4nMUxmakSTyFJrbjJk9oYpTysQmhDfXNsh0bRaxJWFJp_Bj-K3eJ26oS8FJVPTexfHe-7ztCjrUU0tqcRQ6EUSSYNZGJNbZx1dLlE7AAij5B9lzOLsXHeToP-U9tSKtc3Yn9RV3UFn3kY4YVmWCvMTH2IS3iy-n0TfMzwglSGGkN4zRukzsgJWOcZjCZr40vjGGmg78liziXeajVi3k2NgtMqkzE635q2UY6hTv6XqNbOC8_DLr4tybaS6TpfbIXVEl6MuD-Abnlqodk9ywEyx-R31_L9gcNA3UoKKcUZyIsTA3r6QIT8XT1vaxxJvEvWlYUQ_BATg6gfSfXuqlLLHGk2OuZooefYiuMBisoW_zqSvRG0PffZqcUdgsIu9I3ZUvRt0s7bXEg0GLZ0uYKPs4u5hS20Jbh18fkcvru4u0sCtMYIpsK3kWpT3yS63SSe81dkTAPyht3sbfeZDnoYXmqAWq4BSsFmxtwaQQrPBPeSWMlf0J2qrpyTwkFrSqz2gngfi3ygmlvYiGcl4axzGR-RI5XWFDN0HRD9cFynilAlkJkqWQyIkeIITVUjK5ZVZ1wmYHQzVM2Iq_6Fcis3bW2OtQcwDaw7dXWyoOtlcBkdgt8uEUF622hdE_TjMP_V2Shwi3QKtSNwH7mCfsreEPSI_JyDcY3Y-Jb5eolPgIMeIH9ZEdkf6C2zbvh0CVoiM_-__Ajsgucoj5_OP_0nNzFsxsSNg_ITne9dC9AqerMYc8tfwCgtiHF |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Risk+factors+for+thrombotic+microangiopathy+in+allogeneic+hematopoietic+stem+cell+recipients+receiving+GVHD+prophylaxis+with+tacrolimus+plus+MTX+or+sirolimus&rft.jtitle=Bone+marrow+transplantation+%28Basingstoke%29&rft.au=Labrador%2C+J&rft.au=L%C3%B3pez-Corral%2C+L&rft.au=L%C3%B3pez-Godino%2C+O&rft.au=V%C3%A1zquez%2C+L&rft.date=2014-05-01&rft.pub=Nature+Publishing+Group&rft.issn=0268-3369&rft.eissn=1476-5365&rft.volume=49&rft.issue=5&rft.spage=684&rft.epage=690&rft_id=info:doi/10.1038%2Fbmt.2014.17&rft.externalDBID=HAS_PDF_LINK |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0268-3369&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0268-3369&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0268-3369&client=summon |